The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Experience of the use of trabectedin in pretreated unresectable, advanced, or metastatic soft tissue sarcoma in nine centers in Lebanon on a compassionate-use basis.
G. Y. Chahine
No relevant relationships to disclose
M. Ghosn
No relevant relationships to disclose
J. G. Kattan
No relevant relationships to disclose
J. A. Makarem
No relevant relationships to disclose
R. Farah
No relevant relationships to disclose
F. G. Kamar
No relevant relationships to disclose
E. A. Tueni
No relevant relationships to disclose
M. Saade
No relevant relationships to disclose
W. Saad
No relevant relationships to disclose
M. Massoud
No relevant relationships to disclose